

Breast Disease-Oriented Team

Clinical Research Treatment Trial Flowchart

NEOADJUVANT

ADJUVANT

NRG-BR008 (HER2+)
Radiotherapy optimization
 Coord: Stephany Ruiz
 Accrual: 0/5

UCI 21-185 (HER2+)
HER2-targeting antibody drug conjugate
 Coord: Stephany Ruiz/Juan Miranda
 Accrual: 4/5

A011801 (HER2+)
Antibody drug conjugate +
kinase inhibitor
 Coord: Stephany Ruiz
 Accrual: 2/5

CCTG-MA39 (ER+, HER2-)
Regional radiotherapy
 Coord: Stephany Ruiz
 Accrual: 0/5

UCI 22-141 (TNBC)
PDL-1 inhibitor
 Coord: Alexis Chavez
 Accrual: 0/5

UCI 22-111 (ER+/HER2-)
Endocrine deprivation
 Coord: Stephany Ruiz
 Accrual: 0/5

NRG-BR007 (ER+/PR+/HER2-)
Radiation therapy + Endocrine therapy
 Coord: Juan Miranda/Stephany Ruiz
 Accrual: 1/5

1L METASTATIC

2L METASTATIC

3L METASTATIC

ETCTN 10546 (TNBC)Cytidine deaminase (CDA) inhibitor + nucleoside hypomethylating agent (HMA)

Coord: Karla Kaminski/Dorothy Huttar

Accrual: 1/5

UCI 19-145 (HR+/HER2-)CDK 4/6 inhibitor+ER Regulator+Aromatase Inhibitor

Coord: Stephany Ruiz

Accrual: 8/20

UCI 21-212 (TNBC)Antibody drug conjugate

Coord: Stephany Ruiz/Juan Miranda

Accrual: 0/3

UCI 22-139 (HR+/HER2-)PI3K/mTOR inhibitor

Coord: Alexis Chavez

Accrual: 2/5

UCI 22-222 (HR+/HER2-)PI3K inhibitor

Coord: Stephany Ruiz

Accrual: 0/4

UCI 22-114 (ER+/HER2-)Proteasome-mediated degradation

Coord: Alexis Chavez

Accrual: 3/5

1L METASTATIC

2L METASTATIC

3L METASTATIC

UCI 22-09 (TNBC, HR+/HER2-)Antibody drug conjugate

Coord: Juan Miranda

Accrual: 1/5

ETCTN 10302 (TNBC, HR+/HER2-)Bone-targeted alpha particle
emitting radiopharmaceutical

Coord: Alexis Chavez

Accrual: 5/10

S2007 (HER2-)Antibody drug conjugate

Coord: Alexis Chavez

Accrual: 1/5

UCI 21-57 (HER2+, HER2 LOW)IgG1-like antibody + CD47 inhibitor

Coord: Alexis Chavez

Accrual: 4/5

UCI 21-82 (TNBC, ER+/HER2-)XBP1-splicing inhibitor

Coord: Stephany Ruiz/Karla Kaminski

Accrual: 1/5

1L METASTATIC**UCI 22-156 (HER2+)**Tumor infiltrating lymphocyte therapy

Coord: Juan Miranda

Accrual: 0/5

2L METASTATIC**3L METASTATIC****ETCTN 10551 (germline BRCA 1/2+)**

Hu5F9-G4 (magrolimab) recombinant humanized anti-CD47 mAb IgG4

Coord: Alexis Chavez

Accrual: 0/5

BASIC SCIENCE

UCI 18-136

Coord: Billy Joel Sanchez/Caylee Carlton
Accrual: 59/100

UCI 17-05 (BRCA1 -/-, +/-)

Coord: Billy Joel Sanchez
Accrual: 48/75